Nutex Health Inc

The stock is in a Stage 2 uptrend, consolidating in a tight 190–198 range above rising EMAs, forming an ascending continuation pattern that confirms bullish medium-term structure. However, RSI is overbought and price is extended, so disciplined entries after a pullback toward the 9/21-day EMA or lower range support are advised before committing.

• ↑Net income reached $112.6 M in H1 2026, a 3100% YoY rise
• ↑Total patient visits grew 9.6% in Q2 2026 to 99,700
• ↓Total revenue fell 6% YoY to $427.2 M; Q2 down 13.6%